Advertisement
Singapore markets closed

  • Straits Times Index

    3,288.82
    +16.10 (+0.49%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • Dow

    38,503.69
    +263.71 (+0.69%)
     

  • Nasdaq

    15,696.64
    +245.33 (+1.59%)
     

  • Bitcoin USD

    66,395.95
    +137.17 (+0.21%)
     

  • CMC Crypto 200

    1,434.50
    +10.40 (+0.73%)
     

  • FTSE 100

    8,081.65
    +36.84 (+0.46%)
     

  • Gold

    2,332.20
    -9.90 (-0.42%)
     

  • Crude Oil

    83.02
    -0.34 (-0.41%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     

  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

After-hours buzz: KITE, JUNO, COL, TWTR and more

Antonio José Vielma
Spencer Platt | Getty Images

Check out which companies are making headlines after the bell on Monday:

Shares of Rockwell Collins (COL) jumped 8 percent after the bell, following the aerospace company's announcement of a partnership with Stellar Labs to develop a new flight operations management platform in the cloud. This follows news of its partnership last week with Boeing (BA) to install the first touch screens in the cockpits of next-generation airliners.

Twitter (TWTR) saw its stock drop about half a percent after the bell. Rumors continue to swirl about its acquisition. In addition to Apple (AAPL), Facebook (FB), Disney (DIS) and Salesforce (CRM) being named as potential buyers, sources told CNBC that Microsoft (MSFT) is also interested in the social media giant.

Shares of Kite Pharma (KITE) spiked 16 percent after announcing positive results from its new drug, KTE-C19, showing 47 percent complete remission rate for patients with aggressive non-Hodgkin lymphoma. Juno Therapeutics (JUNO), which also develops immunotherapies, saw its stock grow 9 percent in sympathy with the Kite Pharma news.

ADVERTISEMENT

Mylan (MYL) continued its fall today after the bell, trending downward about half a percent. The pharmaceuticals company made news today after filing a new presentation with the SEC that shows Mylan's pre-tax profits for the EpiPen are 60 percent higher than it told Congress in a hearing last week.



More From CNBC

  • Top News and Analysis

  • Latest News Video

  • Personal Finance